Physician profile
Alejandro Munoz
NPI 1568639391
$2,123.29
in general payments reported to CMS, 2019-2025
12 companies · $20.07 in 2025
The $20.07 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $42.01 · 2022: $221 · 2023: $425 · 2024: $348 · 2025: $20.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $855.65 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $331.94 | 2022-2023 | Omnipod |
| Medtronic, INC. | $224.91 | 2023-2024 | Minimed 780g |
| Mannkind Corporation | $126.29 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $125.89 | 2019 | |
| Novo Nordisk INC | $123.34 | 2019 | |
| Beta Bionics, INC. | $82.54 | 2024 | Ilet Bionic Pancreas |
| Amgen INC. | $78.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.08 | 2024 | |
| Lilly USA, LLC | $42.01 | 2020 | |
| Abbott Laboratories | $39.98 | 2019 | |
| Ascendis Pharma Endocrinology INC | $20.07 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.